Jul12Wed

From IrishCentral.com: 2017 Green Card Lottery Results

Anti-American countries get far more green cards than than the Irish do
By Niall O’Dowd
IrishCentral.com

The numbers from the annual diversity lottery visa are out and they make this Irishman’s blood boil. We’ve been had as a nation, as one of the founder countries who helped create this great republic.

What the 1965 immigration reform act has done for the Irish is made new Irish immigrants as scarce as hen’s teeth.

And yes I know, it was Senator Edward Kennedy who played the major role in drafting that law. He tried to reverse its anti-Irish outcome before he died, but it was too late.

Now comes just the latest example. Each year 50,000 US Green Cards are allocated among 35 countries who are disadvantaged by current immigration law.

Read More

Jul12Wed

News from Amicus Therapeutics

Amicus Therapeutics’s stock soars on heavy volume after FDA clears NDA submission for Fabry disease treatment

Shares of Amicus Therapeutics Inc. FOLD, -2.24% shot up 40% toward a 22-month high in active premarket trade Tuesday, after the biotechnology company said the Food and Drug Administration cleared the company to submit a new drug application for its Fabry disease treatment. Volume approached 600,000 shares about 90 minutes before the open, making the stock the most actively traded in the premarket session. The company said it plans to submit an NDA for oral precision medicine migalastat in the fourth quarter of 2017. “We are moving ahead expeditiously with our NDA submission and accelerating the U.S. pathway for migalastat,” said Chief Executive John Crowley. “Today is a seminal moment in the development of migalastat and a testament to the dedication and perseverance of the patients, physicians and employees who have worked so hard on the development of this precision medicine.” The stock had doubled year to date through Monday, while the iShares Nasdaq Biotechnology ETF IBB, +0.25% has climbed 17% and the S&P 500 SPX, +0.62% has gained 8.4%.

 

Jul07Fri

Welcome New Members

Welcome new Irish Chamber members!
Be sure to look out for new members at upcoming events. They will have maroon ribbons on their name tags.

Individual Members

– Robert F. Hart, CFP®, Bernstein Private Wealth Management
– Janice K. Marini, Thomas Jefferson University
– James Harbeson, Bank of America
– Thomas Morrissey, Univest Insurance, Inc.
~~
Mid-Size Firm Members
– U.S. Trust, William Meagher, Michael P. Terry, Catherine Adams Baldry
– The Graham Company, Andrew Corrigan, Kevin Funston, Christopher Whitney
Jul03Mon

Member News from Almac

Breaking News: Almac Discovery is Granted Orphan Drug Designation for ALM201 Programme in Ovarian Cancer 

Craigavon, N.I., UK, 3 Jul 2017 – Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to its drug candidate ALM201 in the treatment of ovarian cancer.

ALM201 is a therapeutic peptide developed to mimic some of the properties of the naturally occurring protein FKBPL. The development of ALM201 by Almac Discovery builds upon initial research work by Professor Tracy Robson who has shown that FKBPL is a naturally secreted protein with effects on a number of important tumour biology processes including cancer stem cells and angiogenesis.

Read More

Jun29Thu

Member News from Aramark

17 Aramark Destinations And Attractions Receive TripAdvisor’s 2017 Certificate Of Excellence

PHILADELPHIA, June 29, 2017 – Aramark (NYSE: ARMK), the award winning food and hospitality partner for national and state parks and other leading leisure and cultural attractions across the country, has received TripAdvisor’s prestigious 2017 Certificate of Excellence Award for 17 of its Aramark-managed properties. Now in its seventh year, this award honors hospitality businesses that have earned great reviews on TripAdvisor, the world’s largest travel site.

Click HERE to read more.

Jun20Tue

Member News from Almac Group

Almac Discovery and Debiopharm International SA Announce a Licensing Agreement for the Development of a Novel Wee-1 Inhibitor

Craigavon, N.I., UK, Lausanne, Switzerland, 20 June 2017 – Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, and Debiopharm International SA, a Switzerland based speciality pharma company, today announced a collaboration to pursue the development of Almac Discovery’s Wee-1 kinase inhibitor programme.

Read More